ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial | Zendy

Paul W. Armstrong | Zendy; Hany Siha | Zendy; Yuling Fu | Zendy; Cynthia M. Westerhout | Zendy; Philippe Gabríel Steg | Zendy; Stefan James | Zendy; Robert F. Storey | Zendy; Jay Horrow | Zendy; Hugo Katus | Zendy; Peter Clemmensen | Zendy; Robert A. Harrington | Zendy; Lars Wallentin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Author(s) -

Paul W. Armstrong,

Hany Siha,

Yuling Fu,

Cynthia M. Westerhout,

Philippe Gabríel Steg,

Stefan James,

Robert F. Storey,

Jay Horrow,

Hugo Katus,

Peter Clemmensen,

Robert A. Harrington,

Lars Wallentin

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.047530

Subject(s) - medicine , ticagrelor , clopidogrel , cardiology , myocardial infarction , hazard ratio , percutaneous coronary intervention , st elevation , acute coronary syndrome , bivalirudin , stroke (engine) , confidence interval , mechanical engineering , engineering

Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial. This prespecified ECG substudy explored whether ticagrelor's association with vascular death and myocardial infarction within 1 year would be amplified by (1) the extent of baseline ST shift and (2) subsequently associated with fewer residual ST changes at hospital discharge.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research